Replimune Group, Inc. (REPL) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
500 Unicorn Park Drive
Woburn, MA 01801
United States of America (the)
Phone
781 222 9600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
479
First IPO Date
July 20, 2018
| Name | Title | Pay | Year Born |
| Sushil Patel | Chief Executive Officer & Director | 1.06M | 1971 |
| Christopher Sarchi | Chief Commercial Officer | 594,578 | 1971 |
| Emily Luisa Hill | Chief Financial Officer | 752,024 | 1980 |
| Konstantinos Xynos | Chief Medical Officer | 781,936 | 1966 |
| Philip Astley-Sparke | Executive Chairman | 960,520 | 1971 |
| Camilo Garcia | Chief Human Resource Officer | 0 | N/A |
| Andrew Schwendenman | Chief Accounting Officer & Treasurer | 0 | 1976 |
| Paul Bullock | Chief Manufacturing Officer & Framingham Site Head | 0 | N/A |
| Shawn Glidden | Senior Vice President & General Counsel | 0 | N/A |
| Carolyn Trott | Senior Vice President of Quality Assurance | 0 | N/A |
| Nina Aragam | Senior Vice President of Portfolio Strategy & Program Management | 0 | N/A |
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.